The evolution of anticoagulant therapy

Blood Transfusion

Volumn 14, Issue 2, 2016, Pages 175-184

  Franchini, Massimo ^a   Liumbruno, Giancarlo M ^b   Bonfanti, Carlo ^a   Lippi, Giuseppe ^c  

^a CARLO POMA HOSPITAL   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

Low molecular weight heparin; New oral anticoagulants; Unfractionated heparin; Vitamin K antagonists; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; ARDEPARIN; ARGATROBAN; BEMIPARIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CERTOPARIN; DABIGATRAN; DABIGATRAN ETEXILATE; DALTEPARIN; EDOXABAN; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; REVIPARIN; RIVAROXABAN; THROMBIN INHIBITOR; TINZAPARIN; WARFARIN; VITAMIN K GROUP;

ANTICOAGULANT THERAPY; ARTERIAL THROMBOEMBOLISM; ATRIAL FIBRILLATION; CLINICAL TRIAL (TOPIC); DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; MEDICATION COMPLIANCE; MEDLINE; META ANALYSIS; PATIENT MONITORING; REVIEW; SYSTEMATIC REVIEW; THROMBOEMBOLISM; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; ANTAGONISTS AND INHIBITORS; HISTORY; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; FACTOR XA INHIBITORS; HEPARIN; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; VENOUS THROMBOEMBOLISM; VITAMIN K;

EID: 84961674065     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2015.0096-15     Document Type: Review

References (81)

1. Mannucci PM, Franchini M. Old and new anticoagulant drugs. Ann Med 2011; 43: 116-23.
2. Lippi G, Franchini M, Targher G. Arterial thrombus formation in cardiovascular disease. Nat Rev Cardiol 2011; 8: 502-12.
3. Lippi G, Franchini M. Pathogenesis of venous thromboembolism: when the cup runneth over. Semin Thromb Hemost 2008; 34: 747-61.
4. Eikelboom JW, Weitz JI. Update on antithrombotic therapy. New anticoagulants. Circulation 2010; 121: 1523-32.
5. Hirsh J. Heparin. N Engl J Med 1991; 324: 1565-74.
6. Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991; 324: 1865-75.
7. nd, Becker RC. Novel oral anticoagulants: pharmacology, coagulation measures, and considerations for reversal. J Thromb Thrombolysis 2014; 37: 380-91.
8. Undas A, Pasierski T, Windyga J, Crowther M. Practical aspects of new oral anticoagulant use in atrial fibrillation. Pol Arch Med Wewn 2014; 124: 124-35.
9. Kornej J, Potpara T, Lip GY. Anticoagulation management in nonvalvular atrial fibrillation: current and future directions. Pol Arch Med Wewn 2013; 123: 623-34.
10. Franchini M, Mannucci PM. A new era for anticoagulants. Eur J Intern Med 2009; 20: 562-68.
11. th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141 (2 Suppl): e24S-43S.
12. th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e419S-94S.
13. th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e495S-530S.
14. Linhardt RJ, Gunay NS. Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost 1999; 25 (Suppl. 3): 5-16.
15. Walenga JM, Lyman GH. Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: A review of pharmacologic and clinical differences and applications in patients with cancer. Crit Rev Oncol Hematol 2013; 88: 1-18.
16. Lyman GH, Khorana AA, Kuderer NM, et al. American Society of Clinical Oncology Clinical Practice: Venous thromboembolism prophylaxis and treatment in patients with cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol 2013; 31: 2189-204.
17. Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 2013; 11: 56-70.
18. Franchini M, Montagnana M, Favaloro EJ, Lippi G. The bidirectional relationship of cancer and hemostasis and the potential role of anticoagulant therapy in moderating thrombosis and cancer spread. Semin Thromb Hemost 2009; 35: 644-53.
19. Franchini M, Mannucci PM. Low molecular weight heparins and cancer: focus on antitumoral effect. Ann Med 2015; 47: 116-21.
20. th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): 7S-47S.
21. th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2912; 141 (2 Suppl): e44S-88S.
22. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492-501.
23. Franchini M, Mengoli C, Cruciani M, et al. Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis. J Thromb Haemost 2014; 12: 1480-7.
24. Hirsh J, O'Donnell M, Weitz JI. New anticoagulants. Blood 2005; 105: 453-63.
25. Petitou M, Duchaussoy P, Herbert JM, et al. The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa. Semin Thromb Haemost 2002; 28: 393-402.
26. Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Semin Thromb Haemost 2008; 34: 39-57.
27. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med 1995; 333: 764-9.
28. Bates SM, Weitz JI. New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin. Br J Pharmacol 2005; 14: 1017-28.
29. Fareed J, Hoppensteadt DA, Fareed D, et al. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Semin Thromb Hemost 2008; 34: 58-73.
30. Hirsh J, O'Donnell M, Eikelboom JW. Beyond unfractionated heparin and warfarin: current and future advances. Circulation 2007; 11 6: 552-60.
31. th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e120S-51S.
32. Eisert WG, Hauel N, Stangier J, et al. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol 2010; 30: 1885-9.
33. Friedman RJ, Dahl OE, Rosencher N, et al.; RE-MOBILIZE, RE-MODEL, RE-NOVATE Steering Committees. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res 2010; 126: 175-82.
34. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the REMODEL randomized trial. J Thromb Haemost 2007; 5: 2178-85.
35. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-56.
36. Ginsberg JS, Davidson BL, Comp PC, et al.; RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009; 24: 1-9.
37. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-52.
38. Schulman S, Kakkar AK, Goldhaber SZ, et al.; RECOVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129: 764-72.
39. Schulman S, Kearon C, Kakkar AJ, et al. Extended use of dabigatran, warfarin or placebo in venous thromboembolism. N Engl J Med 2013; 368: 709-18.
40. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
41. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007; 100: 1419-26.
42. Bloom BJ, Filion KB, Atallah R, Eisenberg MJ. Meta-analysis of randomized controlled trials on the risk of bleeding with dabigatran. Am J Cardiol 2014; 11 3: 1066-74.
43. Connolly SJ, Wallentin L, Ezekowitz MD, et al. The longterm multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study. Circulation 2013; 128: 237-43.
44. Salazar CA, del Aquila D, Cordova EG. Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. Cochrane Database Syst Rev 2014; 3: CD009893.
45. Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolismand pharmacokinetics after oral administration to humans. DrugMetab Dispos 2009; 37: 74-81.
46. Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009; 361: 594-604.
47. Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375: 807-15.
48. Lassen MR, Gallus A, Raskob GE, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363: 2487-98.
49. Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med 2011; 62: 41-57.
50. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799-808.
51. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368: 699-708.
52. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-92.
53. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-17.
54. Bounameaux H, Camm AJ. Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs 2014; 74: 1209-31.
55. Fuji T, Wang CJ, Fujita S, et al. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial. Thromb Res 2014; 134: 1198-204.
56. Fuji T, Wang CJ, Fujita S, et al. Safety and Efficacy of edoxaban, an oral factor Xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan. J Arthroplasty 2014; 29: 2439-46.
57. Büller HR, Décousus H, Grosso MA, et al.; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406-15.
58. Giugliano RP, Ruff CT, Braunwald E, et al.; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-104.
59. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-75.
60. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372: 31-9.
61. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-86.
62. Turpie AG, Lassen MR, Davidson BL, et al.; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373: 1673-80.
63. Turpie AG, Lassen MR, Eriksson BI, et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 2011; 105: 444-53.
64. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-510.
65. The EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-97.
66. Prins MH, Lensing AW, Bauersachs R, et al.; EINSTEIN Investigators. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013; 11: 21.
67. Patel MR, Mahaffey KW, Garg J, et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91.
68. Dentali F, Riva N, Crowther M, et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation 2012; 126: 2381-91.
69. van der Hulle T, Kooiman J, den Exter PL, et al. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 2014; 12: 320-8.
70. Adam SS, McDuffie JR, Ortel TL, Williams JW Jr Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med 2012; 157: 796-807.
71. Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood 2014; 124: 2450-8.
72. Hernandez I, Baik SH, Piñera A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med 2015; 175: 18-24.
73. Chang HY, Zhou M, Tang W, et al. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. BMJ 2015; 350: h1585.
74. Abraham NS, Singh S, Alexander GC, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ 2015; 350: h1857.
75. Franchini M, Velati C. The use of novel oral anticoagulants: the debate continues! Blood Transfus 2015; 13: 170-1.
76. Prandoni P. The treatment of venous thromboembolism with novel oral anticoagulants: warnings and limitations. Blood Transfus 2015; 13: 178-80.
77. Riva N, Ageno W. Which patients with venous thromboembolism should receive non-vitamin K antagonist oral anticoagulants? The majority. Blood Transfus 2015; 13: 181-3.
78. Beyer-Westendorf J, Förster K, Pannach S, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 2014; 124: 955-62.
79. Lippi G, Favaloro EJ. Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus? Clin Chem Lab 2015; 53: 185-97.
80. Lippi G, Favaloro EJ, Mattiuzzi C. Combined administration of antibiotics and direct oral anticoagulants: a renewed indication for laboratory monitoring? Semin Thromb Hemost 2014; 40: 756-65.
81. Lippi G, Ardissino D, Quintavalla R, Cervellin G. Urgent monitoring of direct oral anticoagulants in patients with atrial fibrillation: a tentative approach based on routine laboratory tests. J Thromb Thrombolysis 2014; 38: 269-74.